Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$11.79 -3.0%	$9.42	$3.30 ▼ $12.43	$1.79B	1.79	1.61 million shs	9.53 million shs
IOVA Iovance Biotherapeutics	$1.69 -2.9%	$2.30	$1.64 ▼ $12.51	$564.35M	0.86	8.97 million shs	17.46 million shs
MBX MBX Biosciences	$10.75 -4.8%	$11.09	$4.81 ▼ $27.50	$359.31M	N/A	257,408 shs	1.14 million shs
WVE WAVE Life Sciences	$6.67 -5.1%	$6.70	$4.87 ▼ $16.74	$1.04B	-1.04	1.27 million shs	2.96 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	+13.58%	+23.84%	+58.68%	+225.69%
IOVA Iovance Biotherapeutics	0.00%	-14.65%	-3.54%	-49.25%	-78.93%
MBX MBX Biosciences	0.00%	+10.37%	-14.21%	+45.66%	+1,074,999,900.00%
WVE WAVE Life Sciences	0.00%	+1.52%	+9.70%	-17.45%	+33.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.2927 of 5 stars	1.4	3.0	4.2	2.6	2.5	0.6
IOVA Iovance Biotherapeutics	4.6671 of 5 stars	4.3	1.0	4.2	1.8	4.2	1.3
MBX MBX Biosciences	2.8782 of 5 stars	3.5	0.0	0.0	2.3	3.3	0.6
WVE WAVE Life Sciences	4.3197 of 5 stars	3.5	1.0	4.8	2.0	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	-10.34% Downside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	623.21% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	248.84% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.50	207.35% Upside

Current Analyst Ratings Breakdown

Latest MBX, ADPT, IOVA, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/11/2025	WVE WAVE Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	10.01	N/A	N/A	$1.37 per share	8.61
IOVA Iovance Biotherapeutics	$212.68M	2.65	N/A	N/A	$2.33 per share	0.73
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	$104.94M	9.89	N/A	N/A	$1.37 per share	4.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	8/6/2025 (Estimated)

Latest MBX, ADPT, IOVA, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
MBX MBX Biosciences	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
IOVA Iovance Biotherapeutics	77.03%
MBX MBX Biosciences	N/A
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
IOVA Iovance Biotherapeutics	10.30%
MBX MBX Biosciences	52.19%
WVE WAVE Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

MBX, ADPT, IOVA, and WVE Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Given Outperform Rating at Wedbush

June 24, 2025 | americanbankingnews.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...

June 22, 2025 | manilatimes.netM

Wave Life Sciences Presents Promising Preclinical Data for WVE-007, a Novel siRNA Obesity Treatment at American Diabetes Association Meeting

June 22, 2025 | nasdaq.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...

June 20, 2025 | finance.yahoo.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 20, 2025 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

June 20, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?

June 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in Stock

June 14, 2025 | insidertrades.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Gregory L. Verdine Sells 30,000 Shares

June 13, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Now Covered by Raymond James

June 11, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

June 11, 2025 | marketbeat.com

Brokers Offer Predictions for WVE FY2026 Earnings

June 10, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's Why

June 9, 2025 | marketbeat.com

Two Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 3, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 2, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 31, 2025 | marketbeat.com

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025 | globenewswire.com

Is Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?

May 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

MBX, ADPT, IOVA, and WVE Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$11.79 -0.37 (-3.04%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.80 +0.02 (+0.13%)

As of 04:13 AM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Iovance Biotherapeutics NASDAQ:IOVA

$1.69 -0.05 (-2.87%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.74 +0.05 (+2.96%)

As of 05:01 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

MBX Biosciences NYSE:MBX

$10.75 -0.54 (-4.78%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.88 -0.87 (-8.09%)

As of 04:00 AM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

WAVE Life Sciences NASDAQ:WVE

$6.67 -0.36 (-5.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.46 -1.21 (-18.14%)

As of 04:00 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time